These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Significance and expression of insulin-like growth factor 1 and IGF binding protein 3 in serum of patients with lung cancer].
    Author: Wang H, Wan YX, Zhang QK.
    Journal: Ai Zheng; 2004 Jun; 23(6):710-4. PubMed ID: 15191678.
    Abstract:
    BACKGROUND & OBJECTIVE: Insulin-like growth factors (IGFs) can strongly stimulate the proliferation of a variety of cancer cells, including lung cancer cells. This study was to discuss the possible role of IGFs in lung cancer development. We examined the expression level of IGF(1) and IGF-binding protein 3 (IGFBP(3)) in plasma of the patients with lung cancer and control subjects, and the relation of its level with clinical characteristics and biological behaviors of lung cancer was elucidated. METHODS: Seventy-eight cases with lung cancer (A group), 35 with benign pulmonary disease (B group), and 14 healthy controls (C group) were included in this study. Serum IGF(1) and IGFBP(3) levels were measured with radioimmunoassay (RIA) and immunoradiometricassay (IRMA), respectively. RESULTS: Serum IGF(1) level and IGF(1)/IGFBP(3) ratio in A group [X+/-S,(570.67+/-185.80) microg/L,(0.23+/-0.16)] were significantly higher compared with those of B group[(466.53+/-142.42) microg/L,(0.14+/-7.12E-02)] and those of C group [(427.66+/-141.19) microg/L,(0.12+/-8.2E-02)]. But there was no significance difference (P=0.060) in IGFBP(3) levels between A group [(3133.60+/-1110.30) microg/L], B group [(3694.46+/-1534.03) microg/L], and C group [(4024.67+/-1373.31) microg/L], and there was no significance in the expression of IGF(1) and IGFBP(3) between B group and C group (P >0.05). For the cases with lung cancer in pre-chemotherapy, the serum IGF(1) level was higher in patients with lymphoid node metastasis, and IGFBP(3) level of them was significantly lower than those without metastasis(P< 0.05). Serum IGFBP(3) levels were lowest in the patients with bone metastases [(1933.14+/-715.21) microg/L, P< 0.05]. Fourteen post-chemotherapy patients showed a lower IGF(1) [(480.29+/-117.93)microg/L] than those in pre-chemotherapy[(661.76+/-153.54)microg/L](P< 0.05),whereas IGFBP(3) level was in inverse to IGF(1). CONCLUSION: These results suggested that IGF(1) and IGFBP(3) play important roles in the growth of lung cancer. Serum examination of them may have potential clinical value.
    [Abstract] [Full Text] [Related] [New Search]